Stockreport

Asahi Kasei Completes Acquisition of Aicuris to Advance Its Global Pharmaceutical Strategy

ASAHI KAISEI CRP UNSP/ADR  (AHKSY) 
NASDAQ:AMEX Investor Relations: asahi-kasei.co.jp/asahi/en/ir
PDF Aicuris’s three antiviral assets complement Asahi Kasei’s therapy portfolioAicuris revenue expected to reach $500 million by 2030FDA has granted Priority Review for the [Read more]